Skip to main content

Name
Joseph Nashed

Wed, 09/18/2019 - 12:07

First I’d like to extend my thanks to Dr. Carrier for the wonderful presentation, and for his discussion with us afterwards

Dr. Carrier’s work highlights that Direct oral anticoagulants (DOACs) represent a potential preventative treatment in individuals at high risk for Venous thromboembolism (VTEs) - especially those with cancer. One of the topics that continually kept reappearing was how Dr. Carrier and his team could influence change in clinical practice with his colleagues in oncology. Despite his recent work, and changes in the American Society of Clinical Oncology recommending that DOACs are useful in preventing VTEs in cancer patients, many of Dr. Carriers colleagues and patients seem to remain slightly skeptical about including DOACs in a patient’s treatment. However, in our discussion afterwards, Dr. Carrier reiterated that educating patients and clinical practitioners is a process that involves time and patience. Convincing skeptics is not a new phenomenon in science, and one example that comes to mind is Dr. Barry Marshall’s work on H. Pylori, and convincing his colleagues that the bacteria induced ulcers. Dr. Carrier mentioned that he is hopeful that such education, time and patience can help clinicians and patients alike make the best informed decision in the treatment protocols for cancer patients at high risk of VTEs.

Once again I would like to thank Dr. Carrier for his time and wonderful presentation and discussion.

Name
Joseph Nashed

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.